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Abstract
Nearly every nation is actively working on an e-Health policy or already has one.
Personal Health Records (PHR) are considered as one of the key elements in the
digitisation of the health sector. While nearly every e-Health agenda mentions
privacy and data protection, the real world implementation can differ. A recent
example is the planned launch of the German “Elektronische Patientenakte”
(ePA), which has only limited data control features for the patient in its first
version. This paper gives an overview of how the e-Health policies of the G7
nations handle patient involvement and privacy for their PHR projects. With
this analysis we show that privacy and patient involvement are crucial for the
acceptance of such projects. Finally we propose a data sovereignty framework
with guidelines for PHRs to give a user control over his data and establish trust
in such systems through broad access, fine granular control, informed decision
making, intuitive user experience and comprehensible transparency.
1 Introduction
e-Health applications and their general use is becoming more and more common
and widely available. Nearly every developed country has a national e-Health
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strategy to make use of the data created during a patient’s treatment. There are
enormous expected benefits from the broad availability of electronic health data.
From better data availability for medical research, paperless hospitals that can
easily send data to a patient’s general practitioner to patient centred care where
a patient is in the middle of the treatment and is in possession and control of all
data. While those are just examples it is clear that the potential benefits make
e-Health projects worth to be pursued for a long time period. When looking at
the German national e-Health project, the “Elektronische Patientenakte (ePA)”,
which is set to launch in 2021, it can be easily seen that patient involvement and
privacy controls are controversial topics. To speed up the launch of the ePA
there are several limitations to access right management for the patient in the
initial version.1 A fine granular access management is promised at a later time
but with no concrete dates yet. This lead to a lot of controversy and discussion
from several parties. The German Federal Commissioner for Data Protection
and Freedom of Information Kelber announced that this violates the General
Data Protection Regulation (GDPR) of the EU and that they will pursue legal
checks before the ePA launches.2 It remains to be seen if this will weaken public
trust in the nationwide project. This is only one of the examples that shows that
data sovereignty is an important topic when it comes to digital personal health
records. According to GDPR Article 9, personal medical data is considered
as sensitive data and must not be processed by default. To make processing of
personal health data possible (or the other sensitive data, that is stated in Art. 9)
one of the exclusions of Article 9 Paragraph 1 a) to j) must be fulfilled. One
of these exclusions is the explicit declaration of consent to the data processing
by the affected person. While there are different approaches to the term of
data sovereignty, there is still no clear definition what it means regarding the
processing of medical data. The previous example for Germany and the EU
regulation gives a glimpse of what is considered important in the EU in those
terms. However nearly every country’s e-Health strategy includes a project
similar to the German ePA. Many European countries also define their strategy
1 https://www.heise.de/newsticker/meldung/Elektronische-Patientenakte-Datenhoheit-kommt-
spaeter-4427379.html [Accessed 25 November 2020; In German]
2 https://www.heise.de/news/Datenschutzbeauftragter-kuendigt-Massnahmen-gegen-
Patientendatenschutzgesetz-an-4873642.html [Accessed 25 November 2020; In German]
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with GDPR in mind, but it is interesting how other nations for example the US
handle the topic of patient involvement, control and privacy of personal medical
data. It is also important to analyse if the e-Health programs even have a patient
centred approach or if the focus is more on the broad availability of the data
for doctors and research. This paper will give an in-depth look on the e-Health
strategies of the G7 nations and other examples. Building on this analysis of the
different countries and especially the role of patient involvement and privacy in
those programs, we will define criteria for data sovereignty for personal medical
data. The paper is structured as follows: At first we will define the term data
sovereignty and what it can mean for patient involvement. After this we will
give an overview of e-Health in the G7 nations and other good examples. With
the provided analysis of our findings, we will improve our data sovereignty
definition and discuss our results. We close this paper with a conclusion and an
outlook to further research, that is necessary in this area.
2 Data Sovereignty for Patient Involvement
The term data sovereignty is nowadays mostly used not only for personal data,
but also for the processing of data as an economic good. However for both
use-cases a wide range of control and possibilities to intervene is mandatory.
When looking at the patient’s perspective of data sovereignty, it is necessary to
have a look at what existing regulations enable for the affected person. In the
introduction it was already mentioned that the GDPR requires consent to process
medical data. There are also some requirements for privacy consent in the GDPR.
First every consent must have a specific purpose. Art. 5 Par. 1 b) says that a
purpose has to be unambiguous and that the data is not allowed to be processed
for something that is not consistent with the declared purpose. Furthermore
the data should be limited to what is necessary for this purpose to enable data
minimisation. Another requirement made in Art. 4 Par. 11 is that a consent
should be freely given and express the affected person’s explicit agreement to
the data processing. Besides this it should be always possible for a subject to
withdrawal its consent. Also the Recital 32 indicates that an opt-out principle
for personal data is not allowed. So any pre-ticked boxes or the assumption, that
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remaining silent means confirmation are not lawful. Finally the Article 15 of
GDPR requires that a subject should have the right to access its data to see if
data was processed and for what purpose it was done. It remains to be noted
that while GDPR is a European regulation, the execution between countries can
be different. For example Belgium explicitly requires written consent for the
processing of medical data. Furthermore Belgium also requires direct access for
the patients to their health data, while Portugal limits access to physicians. In
Germany there are also specific laws and regulations that have implications on
the execution on GDPR such as the local hospital regulations or the laws like
the Patientendaten-Schutz Gesetz (PDSG) mentioned in the introduction. Even
with the common GDPR the EU remains fragmented, which makes a closer
look necessary [7]. In terms of digital consent the level of granularity is always
an important topic. The best case would be an arbitrary level of granularity for
consent. This means a patient could choose any data he wants to share with
any third party the patient wishes. In reality those approaches are often limited.
The limitations can have several reasons like technical limitations or limitations
of user interfaces. The German law defines the basic control over personal
data as information self-determination. While this term comes from an age
before personal health records, the basic principles like control and transparency
of data usage remains important. Therefore we consider data sovereignty as
information self-determination + X. While this X seems arbitrary it must be
defined interdisciplinary. There are legal, ethical and technical considerations
that needs to be done. For example not every legal definition can be executed
in the exact same way technically and not every technical possibility comes
without ethical concerns. However the technical side of data sovereignty has
to enable everything needed in terms of consent, with a rich digital consent
management, and transparency with possibilities to automatically track usage of
personal health data. Nevertheless as described before technical solutions alone
are not sufficient, therefore this paper gives an overview of the state of the art
and suggests technical solutions that can help to improve data sovereignty.
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3 e-Health in the G7 Nations
In this section we provide an overview of the e-Health projects in the G7 nations
and other good examples. The overview will be focused on privacy and security
aspects of the different projects.
3.1 Methodology
For our research we choose a qualitative approach. We focused on the G7 nations
since that is where we expected the most resources available in English language
versions. In addition we decided to include a few other notable examples we
found during our research. For our systematic research approach, we used the
directory of e-Health policies by the World Health Organization (WHO), which
was created with information of the states itself or through an online search and
research in academic literature [16]. The directory entry served as starting point
for a general overview. In addition the European Union has a similar overview
for a few selected nations [9]. For a more focused view on privacy policies
regarding e-Health, we did our own literature and online research.
3.2 Germany
As mentioned in the introduction Germany has a lot of ongoing e-Health projects,
but the largest is the national ePA, which is created by a consortium of different
parties called gematik.3 Data protection and privacy is a core topic while
developing the ePA. This policy has a legal foundation in the so called e-Health
law, which requires the highest priority for data protection from a legal and
technical standpoint [2]. The gematik approach to fulfil this requirement is with
the policy that no data should be accessed through the public internet and that
a secure tunnel is required anytime [11]. Nowadays with the rise of mobile
applications this approach is not fully valid anymore, since smartphone apps,




use-case is data usage when visiting a doctor. Access to this data requires two
factors from each party. One factor is the so called “Gesundheitskarte”, which is
a chip card that is also proof of health insurance. When a patient wants to access
his data, he also needs to enter a PIN code. In this scenario the doctor also needs
to prove his/her identity and confirm access with his medical id card, which
is similar to the “Gesundheitskarte”. In addition every access to data of the
personal health record is recorded in a log file. This helps the patient to trace the
usage of his data. In terms of patient control the ePA tries to do a staged rollout
of control mechanism for the initial launch. In the first version only basic access
control is possible. This means that a patient can give a doctor or a different
party full access to every data or no access. This lead to a lot of controversy as
described in the introduction of this paper. In addition the final planned stage
will still lack the option of full control since access rights can only be managed
for several document types like a doctor’s letter, that includes more than one
medical observation and not a fine granular level for every medical resource
of a patient. In 2014 Dehling et al. did an evaluation of the ePA project and
compared it to their approach of patient-centred health information technology
service [5]. They described several requirements on how sensitive medical
information should be handled with a focus on privacy and security. Their result
was that ePA was lacking a lot of things like the possibility for anonymous
data sharing, unlinkability and some things like confidentiality, access control
and authorisation are only partly fulfilled. It remains to be seen how well the
German ePA will be accepted with all its privacy controversy, when it is set to
launch in 2021.
3.3 France
France has several long term national e-Health strategies [8]. It is part of a
digitisation agenda from 2011 where e-Health is a fundamental part. Inside this
e-Health agenda there are five key points and privacy is one of them: “Open
access to health data, respectful of personal information privacy, to serve the
steering of the health care system, as well as public health and research (open
data)” [13]. 2011 was also the year of the introduction of France’s first personal
health record project, the so called Dossier Médical Personel (DMP). The main
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principle of the DMP is not to be a complete health record of a patient, but
rather an exchange and information platform where physicians can include the
information from a patient they consider necessary. It is also a more document
based platform that includes files like physician reports based on international
standards like the Clinical Document Architecture (CDA). The whole DMP is
opt-in and will be created by the general practitioner (GP) if a patient gives
consent. In terms of patient involvement the DMP has an interesting history.
After the initial launch only doctors were able to access a patient’s DMP. There
was no explicit way for a patient to access the records without a doctor. This
caused a very low adaption of the platform, which lead to a relaunch that was
more patient centred and provided direct access for the patient. With this higher
adoption and acceptance was noticeable[3]. This version also included granular
access right management for the patient. First a patient needs to authorise every
physician, so that he can have access. Then every document can have a certain
status. The status can be open so that everyone that has access to the DMP
can access it. Another status is hidden, where only the patient, the physician
that created the document and the GP see the resource. Other doctors see that
there is a hidden file. Lastly there is a confidential status, which can be used
when there is a sensitive diagnosis that should be viewed for the first time in
the presence of the corresponding doctor. In addition to these access rights a
patient can upload own documents and see an access log for every document.
3.4 Italy
Italy currently has no nationwide personal health record project with a focus
on direct patient involvement. However there are different e-Health projects
to introduce a nationwide electronic health record (EHR). The e-Health law
sees three main tasks for an EHR: improvement of treatment, research and
evaluation of the care quality. While there is no direct patient involvement,
patients can control if there is an EHR and what data will be stored there with
their consent. Besides from exceptions for patient care or treatment, the patient
is in the center of the consent decision [1]. It needs to be mentioned that this is a
legal requirement and the patient has no technical way to control this yet. In the
past this lead to cases where EHRs were created without consent. Nevertheless
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the patient has a right to get access to the EHR and privacy is a core principle in
laws and strategies for e-Health. From a technical perspective there is still more
to do to introduce the EHR and to improve direct patient involvement [10].
3.5 United Kingdom
The UK with its centralised National Health Service (NHS) launched several
EHR systems in the past. In 2012 the government released a strategy paper
that described a ten year framework for health and care [6]. Two key points
were that the patient should be in the center of care and that digitisation should
give benefits in a broad spectrum. This starts with tools for patients to make
digital appointments, receive digital prescriptions and self-assessment tools.
Furthermore standardised data communication allows data to improve the quality
of care and reduction of inconsistent or incomplete data for health care providers.
The strategy paper also described privacy concerns as potential issues. The paper
stated the following position regarding those concerns: “not sharing information
has the potential to do more harm than sharing it”. However there are no more
details besides that data should be shared in a confidential and private way and
that patient should control this process. One of the already launched projects is
the Care.data program.4 The project aims to store all data of GPs in a common
centralised database. Patients can deny consent to participate, however data will
then be store anonymised. The focus of Care.data is on the secondary usage
of data. Hoeksma took an in depth look at the program and its implications
on privacy [12]. There is paid access to the platform and it offers matching of
data from different sites to enable longitudinal tracking of patients’ progress.
This was done by using a patient identifier, the NHS number, date of birth, sex,
ethnicity and postcode. After the linkage those identifiers are replaced by a
pseudonym. Overall Hoeksma criticized the platform for its lack of transparency
for the patient. All in all the missing transparency and other issues lead to the
shutdown of the project. Another project that is still in use is the Summary Care
Record. This service is a personal health record platform similar to the system
of Germany’s ePA. It is only created with the patient’s consent, which can have
4 https://www.england.nhs.uk/2013/10/care-data/
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different levels. It is possible to consent to the storage of all information or only
to allow the storage of necessary medical data. Currently the patient has no
independent access to the platform, but can request the stored data from his GP.
There are also some privacy concerns related to the service as the foundation
medConfidential stated when they analysed conformance with the GDPR. 5 In
addition there is access for secondary use for third parties. This is a default and
needs explicit opt-out by the affected person. Like before the opt-out options
have different stages. Opt-out can be universal or the patient can opt-out for
every secondary use except when the explicit purpose is to provide his own
treatment or care. The third-party access also lead to some controversy when
life insurance or credit-card companies gained full access through subject access
requests, that should only provide them the relevant data for the purpose.6
3.6 United States of America
The USA with its federal states has a variety of federal and national privacy laws,
that lead according to Dumortier et al. to problems in regard of the introduction
of e-Health [7]. Additionally many privacy laws are rather old and from a
time before the digitisation. The major regulation in terms of health data is
the Health Insurance Portability and Accountability Act (HIPAA), which has
general privacy rules for personal health data. One of the main principles is
that a patient must give his consent before health data is processed or given
to another party. One exclusion is the usage in the context of a treatment or
to process payment. However the patient should always have a certain degree
of control for sensitive data. HIPAA also regulates when consent is needed
and how a consent has to look like. It gives patients the right to access their
data and the right to correct data. There are special requirements how to use
data for secondary usage and who is allowed to do it. The HIPAA regulation is
created to avoid that personal health data gets into the hands of unauthorised
people. Besides privacy regulation HIPAA also has requirements in terms of
5 https://medconfidential.org
6 https://www.telegraph.co.uk/news/nhs/10855450/Probe-into-claims-that-insurers-given-access-to-
full-medical-records.html [Accessed 25 November 2020]
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security of the data. It remains to be noted that federal law can lead to exclusions
and exceptions of the HIPAA regulation. This makes exchange of health data
between federal states difficult. Besides national projects and strategic plans to
boost the digitisation of the digital health sector, there is an existing solution
called Blue Button.7 This EHR service is created by the Blue Button initiative
and is supported by many health providers on a voluntary basis. If there is a
website that provides the possibility to safely download the personal health data
of patients a blue button appears and enables the possibility to do so. The format
does not necessarily have to be machine readable, it also can be a PDF or a
some other document. Rather than providing a personal health record platform
like in other nations, the intention is to make analogue exchange of health data
easier and enable a possibility for the patient to get access to his data. There
is also a successor in development called Blue Button+ that plans to enable a
digital exchange with explicit control of the affected patient. In addition to the
initiatives of the government there are many projects from private companies
like Apple Health or Microsoft Health Vault to create personal health records.
3.7 Japan
Japan has a long history of the introduction of electronic health record systems.
It already started in 1998 with the development of formats for the EHR. Those
fundamental approaches had considerations about security but obviously did not
look at patients in control of their data. There are regional differences in terms
of e-Health usage. For example there are hospitals that offer their own EHR
where patients have access but there is no nationwide personal health record.
In 2018 the next-generation medical infrastructure law was introduced [15].
After a look at the status quo in terms of e-Health, which showed that only the
minority of hospitals use EHR systems, that most of digital patient data remains
unused and that documentation of patients’ EHR is mostly incomplete, the new
law allowed access to anonymised patient data for secondary usage like research
without explicit consent of a patient. Nevertheless the patient will be informed
about the usage of his data and can intervene - no intervention means consent.
7 https://www.healthit.gov/topic/health-it-initiatives/blue-button
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Most of the system and decisions how to use data remain in the responsibility of
the participating hospitals. They need to decide how to anonymnize the data and
if and how the patient should be involved. A study from Morris et al. showed
that most of Japans population have privacy concerns and favor a system where
they have control [14].
3.8 Canada
Canada has a privacy regulation called Personal Information Protection and
Electronic Document Act (PIPEDA) similar to the HIPAA of the US. The goal
is to protect personal health data from commercial usage without consent [4].
Furthermore there is Canada Infoway, which develops e-Health solutions for
Canada.8 A key goal is that the patient is in the center of the treatment. However
there is currently no nationwide general personal health record.
3.9 Others
Besides the G7 nations there are other good examples for national e-Health
initiatives with patient involvement. One example is Australia which has a
system called My Health Record for a personal health record.9 Privacy is a very
strong requirement there and is enforced by law and technical requirements.
Another example is Estonia, where there is one central platform where every
health data is stored. In terms of privacy this project follows the rule of GDPR.
4 Analysis
When looking at the e-Health policies of the G7 nations and the role of privacy
and patient involvement it becomes clear that nearly every nation applies some
kind of general regulations like the GDPR or more health specific ones like





laws for e-Health. For example Germany has a whole series with the recent
PDSG as example. One interesting observation is that European countries have
different executions of GDPR in terms of e-Health. Another observation is
that there is a gap between technical execution and legal requirements. A good
example where the technical planning is behind the law is the staged launch of
the German ePA in terms of access control. A general impression is that nearly
every personal health record is in an early phase. The DMP in France is a good
example what impact patient involvement has on acceptance. This should be
considered as cautionary example about how a good revamp with the patient
in mind can look like. When looking at projects from the UK the importance
of privacy can be shown by looking at projects cancelled due to privacy issues.
Unfortunately there is no project that meets our requirement for data sovereignty
in terms of data control and an arbitrary level of granularity to do so. The lack
of complete data control is also related to open questions in terms of secondary
usage and data donations. This is a very sensitive topic since there needs to be
a fair trade off between data usage for research, which potentially benefits the
general public in general and protecting data of individuals. The depth of this
controversy can be easily seen by the discussion whether such processes should
be opt-in or opt-out. With the general overview and some failed examples our
research shows strong indications that it is important to involve the patient in a
transparent way instead of hiding such data usage from him.
In general it is shown that technical solutions alone can only be partial solutions.
Another major topic is to intuitively present the technical possibilities to the
user through a suitable user experience. This should help the patient to be in the
position to control his data, but also understand the implications of the control.
To achieve this we propose a data sovereignty framework for personal health
records that gives user control over his data and establishes trust in the system
with the following properties.
• Broad access:
Independent access is mandatory for every aspect a user needs for data
sovereignty. Access should be as easy as using a dedicated app on the
patient’s smartphone. Access exclusively in presence of a physician should
be discouraged because it will not let the user have an independent look
on his data.
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• Fine granular control:
A user should be able to control every access to every datapoint of his
PHR. When a consent for data usage is requested the user should be able
to decide which data is allowed to be used by whom. This also leads to
requirements for the underlying data structure. Documents that combine
different data of patients should be avoided or also offer fine granular
control.
• Informed decision making:
Any decision which is not based on information or deeper knowledge
can not be an informed decision. This property has consent decisions in
mind, which can be very complex and hard to understand for a patient. A
sovereign patient should be able to know what he does at any time. This
should be supported by recommendation systems that evaluate decisions
based on the patients preference. In the concrete case of consent this can
be done by considering the preferences of the user, the requested data and
the purpose of the request.
• Intuitive User Experience:
All possibilities are limited when a user does not understand them. This
is a rather interdisciplinary challenge from an ethical, legal, technical and
design standpoint. For example an access system where the user feels
overwhelmed by the possibilities will not help him to be sovereign. The
mentioned discipline must define the requirements, so that the user has a
good experience.
• Comprehensible transparency:
A patient should be able to reproduce every usage of his data. He should
not only be able to see the first data usage but also what such first data
request imply, for example a research project that gives data to a partner
to process it. This should be supported from a technical perspective and
encouraged by guidelines how to use the data and make it transparent for
the user.
We propose that a PHR that wants to enable patient involvement and data




5 Conclusion & Outlook
This paper gives an overview of privacy and patient involvement in e-Health
worldwide. We see patient involvement, privacy and data control as crucial
key points to enable data sovereignty in terms of PHRs. This term is defined
by analysing the GDPR and how local policies extend it. We showed that
data sovereignty requires more than what is demanded by current laws and
their execution with the example of information self-determination, which is
considered a fundamental right in Germany. From a technical point of view we
see that this concept needs to be extended with a rich digital consent management
and ways to enforce automatic data usage tracking for transparency. It has to
be mentioned that the addition and extensions can not be purely technical and
an interdisciplinary approach is required. Our overview looked at the e-Health
policies of the G7 nations with a focus on privacy and patient involvement. The
overview showed that while nearly every country has one or more laws that
enforces privacy and patient involvement, the implementation is often limited.
There are also clear examples proving that privacy and patient involvement is
a key factor for the acceptance of a PHR. With those results we define a data
sovereignty framework for PHRs. We propose that broad access, fine granular
control, informed decision making, intuitive user experience and comprehensible
transparency can help to give a user control over his data and establishes trust in
the PHR system.
Our results show that more work is required in various fields to define a good
framework for patient involvement and data sovereignty for PHRs. This should
be done in an interdisciplinary effort. On the one hand there is the legal view.
Further research and legislation is required to define the guidelines for the
underlying technological possibilities of a PHR. In addition the ethical view
should also be considered. Questions like what possibilities in terms of data
control and privacy should be, if at all, limited for the patient need to be
investigated. The issue when dealing with the trade off between usability and
pre-filled decisions should be evaluated from an ethical point of view. Finally,
besides the general technological implementation, there needs to be user research
to create a proper user experience. This should investigate how a patient can
be empowered, so he can understand his decision making and data control
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without being overwhelmed by too many possibilities. Besides those open
questions further observation of the current development in e-Health worldwide
is necessary. One thing that could lead to new data on patient acceptance will
be the upcoming launch of the German ePA. With a lot of controversy in terms
of data protection and security, it remains to be seen how the compromises in
those matters affect the adaption and acceptance of the project. While this is
just one example of on-going digitisation, there will be more data and studies
that could be used to refine our presented framework.
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